NR1H4 and metabolic syndrome: In 2015, Genin et al. developed a series of potent FXR agonists to treat dyslipidemia, leading to the identification of LY2562175, now named TERN‐101 (29, Figure 3), a selective FXR agonist with strong lipid‐modulating properties (TT EC50 = 193 nM).[104] In preclinical models, TERN‐101 (29) reduced LDL and triglycerides while increasing HDL levels, showing promising pharmacokinetics (PK) for once‐daily dosing.